Hostname: page-component-7c8c6479df-5xszh Total loading time: 0 Render date: 2024-03-27T03:59:13.030Z Has data issue: false hasContentIssue false

Within-Individual Variation in Steady State Plasma Levels of Different Neuroleptics and Prolactin

Published online by Cambridge University Press:  29 January 2018

R. G. McCreadie
Affiliation:
Crichton Royal Hospital, Dumfries DG1 4TG
Margaret Mackie
Affiliation:
Dumfries and Galloway Royal Infirmary, Dumfries DG1 4AP
David H. Wiles
Affiliation:
Crichton Royal Hospital, Dumfries DG1 4TG
Aksel Jorgensen
Affiliation:
Department of Biochemistry, Lundbeck Limited, Copenhagen
Villy Hansen
Affiliation:
Department of Data Processing, Lundbeck Limited, Copenhagen
Colin Menzies
Affiliation:
Crichton Royal Hospital, Dumfries DG1 4TG

Summary

Eleven male chronic schizophrenics were given, serially, oral pimozide, fluphenazine, and flupenthixol; the two latter were also given intramuscularly as decanoates in oil. Oral haloperidol was given before and after each drug. Analysis of variance of steady state plasma levels of the different neuroleptics showed considerable within-individual variation in such levels, probably due to differences in absorption and metabolism and between routes of administration. The findings suggest that if a patient fails to respond to one neuroleptic, there may be good pharmacokinetic reasons for switching him to another belonging to a different group, or for giving the same neuroleptic by a different route of administration. The study also showed that previous administration of one neurololeptic may influence the steady state level of another. The various neuroleptics produced different effects on plasma prolactin levels.

Type
Papers
Copyright
Copyright © 1984 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andersson, T. W. & Darling, D. A. (1954) A test of goodness of fit. Journal of the American Statistical Association, 49, 765–9.Google Scholar
Cawley, R. H. (1967) The present status of physical methods of treatment of schizophrenia. In: Recent Developments in Schizophrenia. British Journal of Psychiatry Special Publication No. 1 (eds. A. Coppen and A. Walk). Ashford, Kent: Headley Brothers.Google Scholar
Cohen, B. M., Lipinski, J. F., Pope, H. G., Harris, P. Q. & Altesman, R. I. (1980) Neuroleptic blood levels and therapeutic effect. Psycho-pharmacology, 70, 191–3.Google Scholar
Feighner, J. P., Rubins, E., Guze, S. B., Woodruff, R. A. Winokur, G. & Munos, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 5763.Google Scholar
Forsman, A. O. (1976) Individual variability in response to haloperidol. Proceedings of the Royal Society of Medicine, 69, (Suppl 1), 912.Google Scholar
Goldberg, S. C., Frosch, W. A., Drossman, A. K., Schooler, N. R. & Johnson, G. F. S. (1972) Prediction of response to phenothiazines in schizophrenia. Archives of General Psychiatry, 26, 367–73.Google Scholar
Jorgensen, A. (1978) A sensitive and specific radioimmunoassay for cis (z)—flupentixol in human serum. Life Sciences, 23, 1533–42.CrossRefGoogle Scholar
Jorgensen, A. (1980) Pharmacokinetic studies in volunteers of intravenous and oral cis (z)—flupentixol and intra-muscular cis (z)—flupentixol decanoate in viscoleo. European Journal of Clinical Pharmacology, 18, 355–60.Google Scholar
Kolakowska, T., Orr, M., Gelder, M., Heggie, M., Wiles, D. & Franklin, M. (1979) Clinical significance of plasma drug and prolactin levels during acute chlorpromazine treatment: a replication study, British Journal of Psychiatry. 135, 352–9.Google Scholar
Kolakowska, T., Gelder, M. G. & Orr, M. W. (1980) Drug-related and illness-related factors in the outcome of chlorpromazine treatment: testing a model, Psychological Medicine, 10, 335–43.Google Scholar
McCreadie, R. G., Heykants, J. J. P., Chalmers, A. & Anderson, A. M. (1979) Plasma pimozide profiles in chronic schizophrenics. British Journal of Clinical Pharmacology, 7, 533–4.Google Scholar
McNeilly, A. S. & Hagen, C. (1974) Prolactin, TSH, LH and FSH responses to a combined LHRA/TRH test at different stages of the menstrual cycle. Clinical Endocrinology, 3, 427–35.Google Scholar
Michiels, L. J. M., Heykants, J. J. P., Knaeps, A. G. & Janssen, P. A. J. (1975) Radioimmunoassay of the neuroleptic drug pimozide. Life Sciences, 16, 937–44.CrossRefGoogle ScholarPubMed
Michiels, L. J. M., Hendriks, R. & Heykants, J. (1976) Radioimmunoassay of the neuroleptic drug haloperidol. Preclinical report. Belgium: Janssen Pharmaceutica Research Laboratory.Google Scholar
Nelder, J. A. & Wedderburn, R. W. M. (1972) Generalised linear models. Journal of the Royal Statistical Society A 135, Part 3, 370–84.Google Scholar
Smith, R. C., Crayton, J., Dekirmenjian, H., Klass, D. & Davis, J. M. (1979) Blood levels of neuroleptic drugs in non-responding chronic schizophrenic patients. Archives of Central Psychiatry, 36, 579–84.Google Scholar
Usdin, R. (1978) Metabolic pathways of anti-psychotic drugs, In: Psychopharmacology: A generation of progress (eds. M. A. Lipton, A. Di Mascio, and K. F. Killam). New York: Raven Press.Google Scholar
Van Putten, T., May, P. R. A., Marder, S. R., Wilkins, J. N. & Rosenberg, B. J. (1983) Plasma levels of thiothixene by radio receptor assay: clinical usefulness. Psychopharmacology, 79, 40–4.Google Scholar
Veseel, E. S. (1979) Pharmacogenetics: multiple interactions between genes and environment as determinants of drug response. American Journal of Medicine, 66, 183–7.Google Scholar
Wiles, D. H. & Franklin, M. (1978) Radioimmunoassay for fluphenazine in human plasma. British Journal of Clinical Pharmacology, 5, 265–8.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.